Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration

<div>A patient with AMD previously treated with 14 ranibizumab injections and 13 bevacizumab injections shows persistent multilayer fluid on OCT (a). Following three aflibercept injections (b) there was marked reduction in total fluid volume as well as a reduced CRT, 3.43 to 3.07 mm<sup>3</sup> and 405 to 293 <i>μ</i>m, respectively.</div>

Journal of Ophthalmology

fig1

Figure 1

Figure 1: Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration 

Figure 1 | Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration 